Farrerol ameliorates diabetic cardiomyopathy by inhibiting ferroptosis via miR-29b-3p/SIRT1 signaling pathway in endothelial cells

Figure 6 Effects of upregulation or downregulation of miR-29b-3p on histopathology and ferroptosis in diabetic cardiomyopathy mice. A: Representative echocardiographic images for six groups of mice; B and C: Quantification of Left ventricular ejection fraction and left ventricular fractional shortening in mice from specified groups (n = 8); D and E: Masson's trichrome and Sirius red staining was used to detect cardiac fibrosis. Scale bars: 100 μm; F and G: Analysis of serum myocardial enzyme activity creatine kinase-MB and lactate dehydrogenase levels (n = 8); H-K: Representative blot images and quantitative analysis of SIRT1, GPX4 and xCT expression in diabetic hearts from the indicated groups (n = 3). ^aP < 0.05 vs NC; ^bP < 0.05 vs DCM. FA: Farrerol; DCM: Diabetic cardiomyopathy; LVEF: Left ventricular ejection fraction; LVFS: Left ventricular fractional shortening; CK-MB: Creatine kinase-MB; LDH: Lactate dehydrogenase.